Atopic Dermatitis clinical trials

Explore recruiting atopic dermatitis clinical trials.

Recruiting atopic dermatitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atopic Dermatitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IV, non-randomized, open-label multinational trial to assess the mechanism of action for Lebrikizumab in moderate-to-severe atopic dermatitis

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A phase I/II randomized, assessor-blind, vehicle-controlled study to assess the safety, tolerability, and pharmacodynamics of DLQ03 in a wound healing model in patients with mild to moderate atopic dermatitis that are colonized with S. Aureus

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

France

Therapeutic use (Phase IV) EU CTIS Study details

Atopic Dermatitis trials by city

Atopic Dermatitis in Toronto Atopic Dermatitis in Vancouver Atopic Dermatitis in Montreal Atopic Dermatitis in Calgary Atopic Dermatitis in Edmonton Atopic Dermatitis in Ottawa Atopic Dermatitis in Winnipeg Atopic Dermatitis in Quebec City Atopic Dermatitis in Hamilton Atopic Dermatitis in Kitchener Atopic Dermatitis in London Atopic Dermatitis in Halifax Atopic Dermatitis in New York Atopic Dermatitis in Los Angeles Atopic Dermatitis in Chicago Atopic Dermatitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease